These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35597870)

  • 1. Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study.
    Valachis A; Carlqvist P; Ma Y; Szilcz M; Freilich J; Vertuani S; Holm B; Lindman H
    Br J Cancer; 2022 Sep; 127(4):720-725. PubMed ID: 35597870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
    Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
    Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
    Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer.
    Gilbert A; Williams C; Azuero A; Burkard ME; Kenzik K; Garrett-Mayer E; Meersman S; Rocque G
    Clin Breast Cancer; 2021 Aug; 21(4):292-301. PubMed ID: 33309481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
    Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
    Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.
    File DM; Pascual T; Deal AM; Wheless A; Perou CM; Claire Dees E; Carey LA
    Breast Cancer Res Treat; 2022 Nov; 196(1):153-162. PubMed ID: 36008651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
    Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
    Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
    Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of classifiers to optimise the identification and characterisation of metastatic breast cancer in a nationwide administrative registry.
    Valachis A; Carlqvist P; Szilcz M; Freilich J; Vertuani S; Holm B; Lindman H
    Acta Oncol; 2021 Dec; 60(12):1604-1610. PubMed ID: 34549678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
    Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
    Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
    den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
    Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort study of 573 women.
    Weiner CM; Mathewos A; Addissie A; Ayele W; Aynalem A; Wondemagegnehu T; Wienke A; Jemal A; Zerche P; Thomssen C; Seidler A; Kantelhardt EJ
    Breast; 2018 Dec; 42():23-30. PubMed ID: 30149234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.
    de Calbiac O; Lusque A; Mailliez A; Bachelot T; Uwer L; Mouret-Reynier MA; Emile G; Jouannaud C; Gonçalves A; Patsouris A; Diéras V; Leheurteur M; Petit T; Cottu P; Ferrero JM; D'Hondt V; Desmoulins I; Mourato-Ribeiro J; Martin AL; Frenel JS
    JAMA Netw Open; 2022 Sep; 5(9):e2231170. PubMed ID: 36107428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of metaplastic breast carcinoma: A single-center experience.
    Ertas G; Başal FB; Üçer AR; Benzer E; Altundağ MB; Demirci U; Çetin B; Karatas F
    J Cancer Res Ther; 2020; 16(6):1229-1234. PubMed ID: 33342778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.